Traverse Biosciences Secures $500k Seed Financing

Traverse Biosciences has announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. The Research Foundation for the State of New York (RF/SUNY) also participated in the financing, as part of an exclusive license and option agreement executed last year that gave Traverse Biosciences access to the relevant intellectual property for use in animal and human health.

Traverse Biosciences, which began when CEO Joseph Scaduto was serving as a BioEntrepreneur-in-Residence for the Center for Biotechnology, is working to commercialize its proprietary library of Stony Brook University invented chemically-modified curcumins for the treatment of chronic inflammatory conditions and cancers affecting humans and animals.

Read more about Traverse and the recent financing:

 

 

Traverse Biosciences Announces Issuance of U.S. Patent

Traverse Biosciences has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,187,406 entitled, “Curcumin Analogues as Zinc Chelators and Their Uses,” which the company has exclusively licensed from the Research Foundation for the State University of New York (RF/SUNY). The issued patent includes claims that cover the composition of matter of the company’s proprietary library of chemically-modified curcumins, including its lead drug candidate, TRB-N0224.
Read more on the Traverse Biosciences website.

 

Traverse Biosciences Executes Exclusive, Worldwide License Agreement

Traverse Biosciences, founded by Joseph Scaduto – one of the Center for Biotechnology’s first BioEntrepreneurs-in-Residence, announced today that it has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY) for access to the animal health applications of a proprietary library of polyenolic zinc-binding agents. The license agreement also extends Traverse Biosciences the exclusive option to license the human health applications of these promising drug candidates.

The drug compounds were invented by Lorne Golub, DMD, MD (Honorary), Distinguished Professor in the Department of Oral Biology and Pathology in the Stony Brook University School of Dental Medicine, and Francis Johnson, PhD, President of Chem-Master International Inc. and Professor of Chemistry and Pharmacology at Stony Brook. The drugs were developed in concert with the the Center for Biotechnology at Stony Brook University. The Center provided financial support to help the inventors develop their lead compound and for follow-on animal studies.

Click to read the press releases from Stony Brook University and Traverse Biosciences.

Traverse Biosciences receives $205,709 Phase I STTR Award

Traverse Biosciences, founded by the Center’s first appointed BioEntrepreneur-in-Residence Joseph Scaduto, was just awarded a $205,709, Phase I Small Business Technology Transfer (STTR) Award in Partnership with the School of Dental Medicine at Stony Brook University, to evaluate the effectiveness of the company’s lead drug candidate for the treatment of periodontal disease. This is the second Phase I STTR award for Traverse Biosciences this year. The research will be led by Lorne Golub, DMD, MD (Honorary) in the Department of Oral Biology and Pathology, and Ying Gu, PhD, DDS, in the Department of General Dentistry, who will serve as co-principle investigators on the award, in close collaboration with Traverse Biosciences.

“I congratulate Traverse Biosciences on securing a second STTR award to advance their product development and commercialization efforts,” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. He added, “STTR funding represents a significant milestone for graduates of our burgeoning BioEntrepreneur-in-Residence program, which is meant to impact the innovation economy and entrepreneurial ecosystem in the region.”

A full press release can be found here:

http://www.traversebiosciences.com/pr150126perio.html

TraverseBioLogo2

Traverse Biosciences Receives Phase 1 STTR Award

Traverse Biosciences announced today that it has received a $223,979 Phase I Small Business Technology Transfer (STTR) award in partnership with the Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. Funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) will be used to evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, for the treatment of osteoarthritis (OA). The research at the Feinstein Institute will be led by Daniel A. Grande, PhD, Director, Orthopaedic Research Laboratory, who will serve as principle investigator on the award in close collaboration with Traverse Biosciences. Read the full press release: http://www.traversebiosciences.com/pr140728phisttroa.html